A phase II study of gemcitabine plus cisplatin chemotherapy in patients with muscle-invasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response (DDR) gene alterations (Alliance A031701).

Authors

Gopa Iyer

Memorial Sloan Kettering Cancer Center, New York, NY

Gopa Iyer , Karla V. Ballman , Pamela J. Atherton , Katie Murray , Young Kwok , Preston D. Steen , Shiva Baghaie , Jonathan E. Rosenberg , Michael J. Morris

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Association of DNA damage repair (DDR) mutations (mts) and clinical outcomes in CALGB 90601 (Alliance).

First Author: Gopa Iyer

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Randomized phase 2 study of maintenance olaparib vs olaparib plus durvalumab for DNA damage repair (DDR) gene mutated unresectable or metastatic biliary tract cancer (BTC) with durable response to first-line platinum-based chemotherapy: OPTIMUM trial.

First Author: YunJung Kim

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Defects in DNA repair genes and long-term survival in cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer (MIBC).

First Author: Benjamin Miron

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.

First Author: Vincent Chung